What is Thymox?
Laboratoire M2, operating under the Thymox brand, is a pioneer in the development of high-performance, biodegradable antimicrobial solutions. The company distinguishes itself through the use of thymol—a naturally derived active ingredient extracted from thyme oil—to combat bacteria, fungi, and viruses, including COVID-19. Their product portfolio is engineered for high-stakes environments, serving critical sectors such as animal health, agricultural biopesticides, and institutional hard surface disinfection. By prioritizing circular innovation and environmental stewardship, the company has carved out a unique niche in the global chemical market, offering a sustainable alternative that does not compromise on efficacy or safety.
How much funding has Thymox raised?
Thymox has raised a total of $4.6M across 1 funding round:
Series B
$4.6M
Series B (2017): $4.6M with participation from Cycle Capital Management and Desjardinsu2013Innovatech
Key Investors in Thymox
Cycle Capital Management
A venture capital firm founded in 2009 that focuses on building innovative clean technology companies globally, managing a platform of seven investment funds across North America and Europe.
Desjardins-Innovatech
The investment arm of the Desjardins Group, a Canadian cooperative and the largest federation of credit unions in North America, focused on supporting regional innovation and economic development.
What's next for Thymox?
With the recent strategic investment, Thymox is poised to deepen its penetration into the global agricultural and industrial disinfection markets. The company's roadmap likely involves scaling its co-innovation partnerships to integrate its thymol-based technology into a wider array of commercial applications. Furthermore, the firm is expected to leverage its current financial standing to optimize its supply chain and increase production capacity, ensuring it can meet the rising demand for non-toxic, effective sanitation solutions. As the regulatory landscape continues to favor sustainable chemistry, Thymox is well-positioned to capitalize on its early-mover advantage in the green-tech space, potentially exploring new international markets and expanding its research and development efforts to address emerging biological threats.
See full Thymox company page
